{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:13:56Z","timestamp":1790835236234,"version":"4.1.0"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vicebio Ltd"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are two medically important causes of respiratory tract infections and diseases. After more than five decades of research and development, vaccines have recently been approved for the prevention of lower respiratory tract disease caused by RSV. However, vaccines for hMPV remain in early-stage development. Here we describe the design and characterisation as well as pre-clinical development of a bivalent vaccine, VXB-241, comprised of the recombinantly expressed viral fusion proteins from both RSV and hMPV, stabilised in their pre-fusion conformation by combining the use of two technologies, the second-generation molecular clamp (MC2S) and key pre-fusion stabilizing mutations. Each of the two antigens were produced at high yield in a mammalian expression system and purified by an affinity capture resin specific to MC2S. Each antigen was demonstrated to adopt the pre-fusion conformation, which was stable for at least twelve months in liquid formulation at 2\u20138\u00b0C. Head-to-head evaluation in mouse immunogenicity studies showed that the VXB-241 candidate vaccine induced a neutralising immune response that was superior or equivalent to the pre-fusion stabilised comparator antigens for either RSV or hMPV, including the RSVPreF3 antigen of the licensed RSV vaccine, Arexvy (GSK). The results presented here have supported progression of VXB-241 into a Phase 1 clinical trial which commenced enrolment in August 2024 (ClinicalTrials.gov ID NCT06556147).<\/jats:p>","DOI":"10.1371\/journal.ppat.1013312","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:50:05Z","timestamp":1752774605000},"page":"e1013312","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus"],"prefix":"10.1371","volume":"21","author":[{"given":"Andrew","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharada","family":"Kolekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alvarez","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Jaberolansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naphak","family":"Modhiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McCuaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Kommajosyula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tardiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quimbe","family":"Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto A.","family":"Amarilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon L.","family":"Dalrymple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Magdalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vandendriessche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Smal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Watterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel J.","family":"Hanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8636-5067","authenticated-orcid":true,"given":"Keith J.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"17","key":"ppat.1013312.ref001","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"AR Falsey","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"ppat.1013312.ref002","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12877-019-1236-6","article-title":"The burden of respiratory infections among older adults in long-term care: a systematic review","volume":"19","author":"A Childs","year":"2019","journal-title":"BMC Geriatr"},{"issue":"4","key":"ppat.1013312.ref003","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12038-008-0067-y","article-title":"Human metapneumovirus: a new respiratory pathogen","volume":"33","author":"S Broor","year":"2008","journal-title":"J Biosci"},{"issue":"3","key":"ppat.1013312.ref004","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CMR.00014-06","article-title":"Epidemiology of human metapneumovirus","volume":"19","author":"JS Kahn","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"ppat.1013312.ref005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.12688\/f1000research.12625.1","article-title":"Human metapneumovirus - what we know now","volume":"7","author":"N Shafagati","year":"2018","journal-title":"F1000Res"},{"issue":"10340","key":"ppat.1013312.ref006","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Y Li","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"ppat.1013312.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(20)30393-4","article-title":"Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study","volume":"9","author":"X Wang","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"1","key":"ppat.1013312.ref008","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60\u2009years and older in high-income countries: A systematic literature review and meta-analysis","volume":"17","author":"M Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"ppat.1013312.ref009","first-page":"43","article-title":"Epidemiologic Analysis of Respiratory Viral Infections Mainly in Hospitalized Children and Adults in a Midwest University Medical Center After the Implementation of a 14-Virus Multiplex Nucleic Acid Amplification Test","volume":"147","author":"S Arbefeville","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"ppat.1013312.ref010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/jis309","article-title":"Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults","volume":"206","author":"K Widmer","year":"2012","journal-title":"J Infect Dis"},{"issue":"10","key":"ppat.1013312.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates","volume":"18","author":"NI Mazur","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ppat.1013312.ref012","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41541-023-00734-7","article-title":"The road to approved vaccines for respiratory syncytial virus","volume":"8","author":"TJ Ruckwardt","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"7","key":"ppat.1013312.ref013","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults","volume":"388","author":"A Papi","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"ppat.1013312.ref014","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults","volume":"388","author":"EE Walsh","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"ppat.1013312.ref015","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"E Wilson","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"ppat.1013312.ref016","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"B Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"ppat.1013312.ref017","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"M Magro","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"309","key":"ppat.1013312.ref018","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"JO Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7","key":"ppat.1013312.ref019","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac206","article-title":"Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults","volume":"9","author":"A August","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"ppat.1013312.ref020","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf160","article-title":"A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60-75 Years of Age","volume":"12","author":"C Shapiro","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"39","key":"ppat.1013312.ref021","article-title":"Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses","volume":"118","author":"GBE Stewart-Jones","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ppat.1013312.ref022","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41467-022-28931-3","article-title":"Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins","volume":"13","author":"C-L Hsieh","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"ppat.1013312.ref023","article-title":"Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus","volume":"19","author":"L Ou","year":"2023","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1013312.ref024","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1038\/s41467-024-50659-5","article-title":"Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer","volume":"15","author":"MJG Bakkers","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"ppat.1013312.ref025","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41467-022-30205-x","article-title":"Profiling of hMPV F-specific antibodies isolated from human memory B cells","volume":"13","author":"X Xiao","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"ppat.1013312.ref026","article-title":"Neutralising antibodies against human metapneumovirus","volume":"4","author":"L Guo","year":"2023","journal-title":"Lancet Microbe"},{"issue":"9","key":"ppat.1013312.ref027","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2022.07.003","article-title":"Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein","volume":"55","author":"CG Rappazzo","year":"2022","journal-title":"Immunity"},{"issue":"10","key":"ppat.1013312.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008942","article-title":"Antibody recognition of the Pneumovirus fusion protein trimer interface","volume":"16","author":"J Huang","year":"2020","journal-title":"PLoS Pathog"},{"issue":"10","key":"ppat.1013312.ref029","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"KJ Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ppat.1013312.ref030","doi-asserted-by":"crossref","first-page":"963023","DOI":"10.3389\/fimmu.2022.963023","article-title":"A platform technology for generating subunit vaccines against diverse viral pathogens","volume":"13","author":"A Young","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"ppat.1013312.ref031","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41541-021-00395-4","article-title":"Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses","volume":"6","author":"CLD McMillan","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"6158","key":"ppat.1013312.ref032","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"JS McLellan","year":"2013","journal-title":"Science"},{"issue":"9","key":"ppat.1013312.ref033","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV","volume":"23","author":"MG Joyce","year":"2016","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"ppat.1013312.ref034","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/s41467-017-01708-9","article-title":"Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein","volume":"8","author":"MB Battles","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"ppat.1013312.ref035","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1128\/AAC.49.11.4700-4707.2005","article-title":"Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency","volume":"49","author":"A Mej\u00edas","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"6136","key":"ppat.1013312.ref036","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"JS McLellan","year":"2013","journal-title":"Science"},{"key":"ppat.1013312.ref037","doi-asserted-by":"crossref","first-page":"16272","DOI":"10.1038\/nmicrobiol.2016.272","article-title":"Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus","volume":"2","author":"X Wen","year":"2017","journal-title":"Nat Microbiol"},{"issue":"7","key":"ppat.1013312.ref038","article-title":"Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein","volume":"11","author":"MSA Gilman","year":"2015","journal-title":"PLoS Pathog"},{"issue":"15","key":"ppat.1013312.ref039","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1128\/JVI.00106-07","article-title":"A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo","volume":"81","author":"JV Williams","year":"2007","journal-title":"J Virol"},{"issue":"25","key":"ppat.1013312.ref040","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203326119","article-title":"Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus","volume":"119","author":"A Banerjee","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ppat.1013312.ref041","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract","volume":"368","author":"H Wu","year":"2007","journal-title":"J Mol Biol"},{"key":"ppat.1013312.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/bmb\/ldh021","article-title":"Bacterial polysaccharide-protein conjugate vaccines","volume":"70","author":"A Finn","year":"2004","journal-title":"Br Med Bull"},{"issue":"12","key":"ppat.1013312.ref043","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3390\/vaccines9121490","article-title":"Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities","volume":"9","author":"M Ghattas","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"ppat.1013312.ref044","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","article-title":"Current Developments and Challenges of mRNA Vaccines","volume":"24","author":"J Chen","year":"2022","journal-title":"Annu Rev Biomed Eng"},{"issue":"12","key":"ppat.1013312.ref045","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1073\/pnas.94.12.6065","article-title":"Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli","volume":"94","author":"W Weissenhorn","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ppat.1013312.ref046","doi-asserted-by":"crossref","first-page":"8991","DOI":"10.1074\/jbc.M311791200","article-title":"Formation of highly stable chimeric trimers by fusion of an adenovirus fiber shaft fragment with the foldon domain of bacteriophage t4 fibritin","volume":"279","author":"K Papanikolopoulou","year":"2004","journal-title":"J Biol Chem"},{"key":"ppat.1013312.ref047","article-title":"Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis","author":"JKH Lee","year":"2021","journal-title":"Vaccine"},{"issue":"16","key":"ppat.1013312.ref048","doi-asserted-by":"crossref","first-page":"10678","DOI":"10.1128\/JVI.79.16.10678-10689.2005","article-title":"An S101P substitution in the putative cleavage motif of the human metapneumovirus fusion protein is a major determinant for trypsin-independent growth in vero cells and does not alter tissue tropism in hamsters","volume":"79","author":"JH Schickli","year":"2005","journal-title":"J Virol"},{"issue":"22","key":"ppat.1013312.ref049","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1128\/JVI.01287-06","article-title":"Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH","volume":"80","author":"RM Schowalter","year":"2006","journal-title":"J Virol"},{"issue":"12","key":"ppat.1013312.ref050","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01052-23","article-title":"Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface","volume":"97","author":"X Xiao","year":"2023","journal-title":"J Virol"},{"issue":"12","key":"ppat.1013312.ref051","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1038\/s41564-024-01860-1","article-title":"A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses","volume":"9","author":"MJG Bakkers","year":"2024","journal-title":"Nat Microbiol"},{"issue":"23","key":"ppat.1013312.ref052","doi-asserted-by":"crossref","first-page":"12236","DOI":"10.1128\/JVI.01579-10","article-title":"Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F","volume":"84","author":"JS McLellan","year":"2010","journal-title":"J Virol"},{"issue":"12","key":"ppat.1013312.ref053","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/nsmb.1950","article-title":"Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies","volume":"17","author":"G Frey","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"ppat.1013312.ref054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"J ter Meulen","year":"2006","journal-title":"PLoS Med"},{"issue":"50","key":"ppat.1013312.ref055","doi-asserted-by":"crossref","first-page":"25057","DOI":"10.1073\/pnas.1912503116","article-title":"A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex","volume":"116","author":"VA Avanzato","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"ppat.1013312.ref056","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1128\/JVI.00700-11","article-title":"A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin","volume":"85","author":"JC Krause","year":"2011","journal-title":"J Virol"},{"key":"ppat.1013312.ref057","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jim.2010.02.001","article-title":"A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies","volume":"354","author":"ML Jones","year":"2010","journal-title":"J Immunol Methods"},{"issue":"1","key":"ppat.1013312.ref058","doi-asserted-by":"crossref","first-page":"11130","DOI":"10.1038\/s41598-017-10415-w","article-title":"Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein","volume":"7","author":"N Jaberolansar","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"ppat.1013312.ref059","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1269","article-title":"Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2","volume":"10","author":"D Watterson","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"10","key":"ppat.1013312.ref060","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3390\/v13101942","article-title":"Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates","volume":"13","author":"A Isaacs","year":"2021","journal-title":"Viruses"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:50:14Z","timestamp":1752774614000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013312"}},"subtitle":[],"editor":[{"given":"Matthias Johannes","family":"Schnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1013312","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}